Allogene Therapeutics Inc. has reported its financial results for the second quarter of 2025, showing a net loss of $50.9 million, or $0.23 per share. This loss includes $8.7 million in non-cash stock-based compensation expense and a $2.4 million non-cash impairment of long-lived asset expense. The company's research and development expenses totaled $40.2 million, which includes $2.6 million of non-cash stock-based compensation expense. General and administrative expenses were $14.3 million, including $6.1 million of non-cash stock-based compensation expense. As of June 30, 2025, Allogene had $302.6 million in cash, cash equivalents, and investments. The quarter highlighted significant progress for Allogene, with advancements in the streamlined ALPHA3 trial, initiation of clinical enrollment in autoimmune indications with ALLO-329, and alignment with the FDA on a pivotal path for ALLO-316 in solid tumors.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allogene Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9511895-en) on August 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.